PL2895192T3 - Kompozycja farmaceutyczna zawierająca stałą nanocząstkę i co najmniej antygen do leczenia przeciwko wewnątrzkomórkowemu czynnikowi patogennemu - Google Patents

Kompozycja farmaceutyczna zawierająca stałą nanocząstkę i co najmniej antygen do leczenia przeciwko wewnątrzkomórkowemu czynnikowi patogennemu

Info

Publication number
PL2895192T3
PL2895192T3 PL13795566T PL13795566T PL2895192T3 PL 2895192 T3 PL2895192 T3 PL 2895192T3 PL 13795566 T PL13795566 T PL 13795566T PL 13795566 T PL13795566 T PL 13795566T PL 2895192 T3 PL2895192 T3 PL 2895192T3
Authority
PL
Poland
Prior art keywords
antigen
pharmaceutical composition
pathogenic agent
treatment against
solid nanoparticle
Prior art date
Application number
PL13795566T
Other languages
English (en)
Inventor
Didier Betbeder
Isabelle Dimier-Poisson
Céline Ducournau
Original Assignee
Université de Lille
Université De Tours Francois Rabelais
Centre Hospitalier Regional Universitaire De Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université de Lille, Université De Tours Francois Rabelais, Centre Hospitalier Regional Universitaire De Lille filed Critical Université de Lille
Publication of PL2895192T3 publication Critical patent/PL2895192T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13795566T 2012-09-17 2013-09-13 Kompozycja farmaceutyczna zawierająca stałą nanocząstkę i co najmniej antygen do leczenia przeciwko wewnątrzkomórkowemu czynnikowi patogennemu PL2895192T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12370002.3A EP2708237A1 (en) 2012-09-17 2012-09-17 Pharmaceutical composition for its use in the preventive treatment of infections caused by an intracellular pathogen, more particularly Toxoplasma gondii
PCT/IB2013/002372 WO2014041427A1 (en) 2012-09-17 2013-09-13 A pharmaceutical composition comprising a solid nanoparticle and at least an antigen for the treatment against an intracellular pathogenic agent
EP13795566.2A EP2895192B1 (en) 2012-09-17 2013-09-13 A pharmaceutical composition comprising a solid nanoparticle and at least an antigen for the treatment against an intracellular pathogenic agent

Publications (1)

Publication Number Publication Date
PL2895192T3 true PL2895192T3 (pl) 2019-03-29

Family

ID=46940433

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13795566T PL2895192T3 (pl) 2012-09-17 2013-09-13 Kompozycja farmaceutyczna zawierająca stałą nanocząstkę i co najmniej antygen do leczenia przeciwko wewnątrzkomórkowemu czynnikowi patogennemu

Country Status (12)

Country Link
US (1) US9731005B2 (pl)
EP (2) EP2708237A1 (pl)
CN (2) CN104736170B (pl)
AU (1) AU2013316781B2 (pl)
CA (1) CA2884786C (pl)
DK (1) DK2895192T3 (pl)
ES (1) ES2672293T3 (pl)
HU (1) HUE042638T2 (pl)
NZ (1) NZ705930A (pl)
PL (1) PL2895192T3 (pl)
PT (1) PT2895192T (pl)
WO (1) WO2014041427A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018104762A1 (en) 2016-12-09 2018-06-14 Universite De Lille 2 Droit Et Sante Cationic nanoparticles for enhancing infectious capacity of viruses
CN115427070A (zh) * 2020-04-20 2022-12-02 英特维特国际股份有限公司 抗猪肺炎支原体疫苗
FR3112284B1 (fr) 2020-07-10 2024-02-09 Vaxinano Procede de preparation d’une composition vaccinale a partir d’antigenes lyophilises
FR3115681B1 (fr) * 2020-11-04 2024-12-20 Vaxinano Vaccin therapeutique comprenant un antigene specifique d’une maladie n’atteignant pas le systeme nerveux central et des nanoparticules et son utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9803232A (pt) * 1997-08-26 2000-01-11 Pfizer Prod Inc Vaicna de neospora.
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics

Also Published As

Publication number Publication date
AU2013316781A1 (en) 2015-04-02
HK1211220A1 (en) 2016-05-20
AU2013316781B2 (en) 2018-03-15
DK2895192T3 (en) 2018-06-18
CN110075286A (zh) 2019-08-02
CA2884786A1 (en) 2014-03-20
US20150238598A1 (en) 2015-08-27
PT2895192T (pt) 2018-06-14
WO2014041427A1 (en) 2014-03-20
EP2708237A1 (en) 2014-03-19
ES2672293T3 (es) 2018-06-13
CN104736170B (zh) 2020-03-17
US9731005B2 (en) 2017-08-15
EP2895192A1 (en) 2015-07-22
HUE042638T2 (hu) 2019-07-29
NZ705930A (en) 2018-06-29
EP2895192B1 (en) 2018-03-28
CN104736170A (zh) 2015-06-24
CA2884786C (en) 2021-11-02

Similar Documents

Publication Publication Date Title
IL274988A (en) Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
IL237522A0 (en) Bioconjugates involving adapted antigens and their uses
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
SG11201405159WA (en) Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging
EP3068442A4 (en) Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
GB201215289D0 (en) Nanoparticle formulation
IL251974B (en) Antifibrosis compounds and their uses
PL2739615T3 (pl) Fenylo-3-aza-bicyklo[3.1.0]heks-3-ylo-metanony i ich zastosowanie jako leki
IL228666A (en) Pharmaceuticals for the prevention and / or treatment of HIV in humans
IL246286A0 (en) A medical preparation for the prevention and treatment of advanced myopia.
PT2895192T (pt) Uma composição farmacêutica compreendendo uma nanopartícula sólida e pelo menos um antígeno para o tratamento contra um agente patogénico intracelular
IL235812A0 (en) Preparations and methods for increasing the effectiveness of bactericidal contraceptives
ZA201503799B (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
ZA201307390B (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
GB201206806D0 (en) Device for the prevention and cure of motion sickness
UA24764S (uk) Упаковка для лікарського засобу «трастумаб»
GB201223447D0 (en) Conjugate compounds for targeted drug deliver and uses thereof
UA25378S (uk) Упаковка для лікарського засобу «лінезолідин»
ZA201105598B (en) Prolonged release pharmaceutical composition comprising galantamine and method for the preparation thereof